Is PML a tumor suppressor?

Frontiers in Oncology

Volumn 3 JUL, Issue , 2013, Pages

  Mazza, Massimiliano ^a   Pelicci, Pier Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cancer; Cancer stem cells; Cancer therapy; PML; Tumor suppressor

Indexed keywords

CASPASE 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; INOSITOL 1, 4, 5 TRISPHOSPHATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P21; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CARCINOGENESIS; CELL CYCLE CHECKPOINT; CELL DEATH; CHRONIC MYELOID LEUKEMIA; DNA REPAIR; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REMISSION; REVIEW; SENESCENCE; TELOMERE HOMEOSTASIS; TRIPLE NEGATIVE BREAST CANCER; VIRUS INFECTION;

EID: 84891107383     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00174     Document Type: Review

References (101)

1. Boveri T. The Origin of Malignant Tumors. Baltimore, MD: Williams and Williams (1929).
2. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. Suppression of malignancy by cell fusion. Nature (1969) 223(5204):363-8. doi:10.1038/223363a0
3. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 68(4):820-3. doi:10.1073/pnas.68.4.820
4. Knudson AG. The genetics of childhood cancer. Cancer (1975) 35(Suppl 3):1022-6. doi:10.1002/1097-0142(197503)35:3<1022::AID-CNCR2820350726>3.0.CO;2-A
5. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A (1993) 90(23):10914-21. doi:10.1073/pnas.90.23.10914
6. Murphree AL, Benedict WF. Retinoblastoma: clues to human oncogenesis. Science (1984) 223(4640):1028-33. doi:10.1126/science.6320372
7. Haber D, Harlow E. Tumour-suppressor genes: evolving definitions in the genomic age. Nat Genet (1997) 16(4):320-2. doi:10.1038/ng0897-320
8. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature (1997) 386(6627):761, 763.
9. Hatta Y, Takeuchi S, Yokota J, Koeffler HP. Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. Br J Cancer (1997) 75(9):1256-62. doi:10.1038/bjc.1997.214
10. Kibel AS, Freije D, Isaacs WB, Bova GS. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer (1999) 25(3):270-6. doi:10.1002/(SICI)1098-2264(199907)25:3<270::AID-GCC9>3.0.CO;2-Z
11. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res (1995) 55(6):1206-10.
12. Takeuchi S, Bartram CR, Wada M, Reiter A, Hatta Y, Seriu T, et al. Allelotype analysis of childhood acute lymphoblastic leukemia. Cancer Res (1995) 55(22):5377-82.
13. Alsheich-Bartok O, Haupt S, Alkalay-Snir I, Saito S, Appella E, Haupt Y. PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene (2008) 27(26):3653-61. doi:10.1038/sj.onc.1211036
14. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med (1999) 50:401-23. doi:10.1146/annurev.med.50.1.401
15. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature (1998) 396(6707):177-80. doi:10.1038/24179
16. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev (1999) 13(20):2658-69. doi:10.1101/gad.13.20.2658
17. Inoue K, Wen R, Rehg JE, Adachi M, Cleveland JL, Roussel MF, et al. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev (2000) 14(14):1797-809.
18. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci U S A (2000) 97(9):4742-7. doi:10.1073/pnas.080063497
19. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci U S A (2001) 98(18):10250-5. doi:10.1073/pnas.191345898
20. Yan H, Dobbie Z, Gruber SB, Markowitz S, Romans K, Giardiello FM, et al. Small changes in expression affect predisposition to tumorigenesis. Nat Genet (2002) 30(1):25-6. doi:10.1038/ng799
21. Quon KC, Berns A. Haplo-insufficiency? Let me count the ways. Genes Dev (2001) 15(22):2917-21. doi:10.1101/gad.949001
22. Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, Scott G, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer (1999) 26(4):286-94. doi:10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.3.CO;2-O
23. Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, et al. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer (2001) 92(3):479-87. doi:10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G
24. Spring K, Ahangari F, Scott SP, Waring P, Purdie DM, Chen PC, et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet (2002) 32(1):185-90. doi:10.1038/ng958
25. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 1(7):686-92. doi:10.1038/nm0795-686
26. Occhionorelli M, Santoro F, Pallavicini I, Gruszka A, Moretti S, Bossi D, et al. The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. Leukemia (2011) 25(5):814-20. doi:10.1038/leu
27. Sternsdorf T, Phan VT, Maunakea ML, Ocampo CB, Sohal J, Silletto A, et al. Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell (2006) 9(2):81-94. doi:10.1016/j.ccr.2005.12.030
28. Rego EM, Wang ZG, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 193(4):521-9. doi:10.1084/jem.193.4.521
29. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 96(4):269-79. doi:10.1093/jnci/djh043
30. Lim JH, Liu Y, Reineke E, Kao H-Y. Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover. J Biol Chem (2011) 286(52):44403-11. doi:10.1074/jbc.M111.289512
31. Reineke EL, Lam M, Liu Q, Liu Y, Stanya KJ, Chang K-S, et al. Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol Cell Biol (2008) 28(3):997-1006. doi:10.1128/MCB.01848-07
32. Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol (2009) 19(4):204-10. doi:10.1016/j.semradonc.2009.05.004
33. Carracedo A, Weiss D, Leliaert AK, Bhasin M, de Boer VCJ, Laurent G, et al. A metabolic prosurvival role for PML in breast cancer. J Clin Invest (2012) 122(9):3088-100. doi:10.1172/JCI62129
34. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 453(7198):1072-8. doi:10.1038/nature07016
35. Regad T, Bellodi C, Nicotera P, Salomoni P. The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat Neurosci (2009) 12(2):132-40. doi:10.1038/nn.2251
36. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, et al. Role of PML in cell growth and the retinoic acid pathway. Science (1998) 279(5356):1547-51. doi:10.1126/science.279.5356.1547
37. Insinga A, Pelicci PG, Inucci S. Leukemia-associated fusion proteins. Multiple mechanisms of action to drive cell transformation. Cell Cycle (2005) 4(1):67-9. doi:10.4161/cc.4.1.1400
38. Fisher GH, Orsulic S, Holland E, Hively WP, Li Y, Lewis BC, et al. Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene (1999) 18(38):5253-60. doi:10.1038/sj.onc.1203087
39. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 126(2):269-83. doi:10.1016/j.cell.2006.05.041
40. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res (1999) 59(6):1206-11.
41. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. Tsc2(±) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest (1999) 104(6):687-95. doi:10.1172/JCI7319
42. Bernardi R, Papa A, Egia A, Coltella N, Teruya-Feldstein J, Signoretti S, et al. Pml represses tumour progression through inhibition of mTOR. EMBO Mol Med (2011) 3(5):249-57. doi:10.1002/emmm.201100130
43. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 14(16):2015-27.
44. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem (2003) 278(35):33134-41. doi:10.1074/jbc.M301264200
45. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J (2000) 19(22):6185-95. doi:10.1093/emboj/19.22.6185
46. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell (1997) 90(4):595-606. doi:10.1016/S0092-8674(00)80521-8
47. Pearson M, Pelicci PG. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene (2001) 20(49):7250-6. doi:10.1038/sj.onc.1204856
48. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 406(6792):207-10. doi:10.1038/35018127
49. Möller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Dröge W, et al. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res (2003) 63(15):4310-4.
50. Yang S, Jeong J-H, Brown AL, Lee C-H, Pandolfi PP, Chung JH, et al. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. J Biol Chem (2006) 281(36):26645-54. doi:10.1074/jbc.M604391200
51. Bernardi R, Pandolfi PP. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene (2003) 22(56):9048-57. doi:10.1038/sj.onc.1207106
52. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays (2004) 26(9):963-77. doi:10.1002/bies.20089
53. Kurki S, Latonen L, Laiho M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J Cell Sci (2003) 116(Pt 19):3917-25. doi:10.1242/jcs.00714
54. Everett RD, Meredith M, Orr A, Cross A, Kathoria M, Parkinson J. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J (1997) 16(3):566-77. doi:10.1093/emboj/16.7.1519
55. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature (2002) 416(6881):648-53. doi:10.1038/nature737
56. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G, et al. PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 13(4):523-35. doi:10.1016/S1097-2765(04)00062-0
57. Crowder C, Dahle O, Davis RE, Gabrielsen OS, Rudikoff S. PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood (2005) 105(3):1280-7. doi:10.1182/blood-2004-04-1614
58. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, et al. PML is essential for multiple apoptotic pathways. Nat Genet (1998) 20(3):266-72. doi:10.1038/3030
59. Lin H-K, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 431(7005):205-11. doi:10.1038/nature02783
60. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 441(7092):523-7. doi:10.1038/nature04809
61. Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene (2008) 27(50):6407-18. doi:10.1038/onc.2008.308
62. Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, Rizzuto R. The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. EMBO J (2001) 20(11):2690-701. doi:10.1093/emboj/20.11.2690
63. Giorgi C, Ito K, Lin H-K, Santangelo C, Wieckowski MR, Lebiedzinska M, et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 330(6008):1247-51. doi:10.1126/science.1189157
64. Pinton P, Giorgi C, Pandolfi PP. The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites. Cell Death Differ (2011) 18(9):1450-6. doi:10.1038/cdd.2011.31
65. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de Thé H. PML induces a novel caspase-independent death process. Nat Genet (1998) 20(3):259-65. doi:10.1038/3068
66. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol (1999) 17:781-828. doi:10.1146/annurev.immunol.17.1.781
67. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. Deconstructing PML-induced premature senescence. EMBO J (2002) 21(13):3358-69. doi:10.1093/emboj/cdf341
68. Mallette FA, Goumard S, Gaumont-Leclerc M-F, Moiseeva O, Ferbeyre G. Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene (2004) 23(1):91-9. doi:10.1038/sj.onc.1206886
69. Vernier M, Bourdeau V, Gaumont-Leclerc M-F, Moiseeva O, Bégin V, Saad F, et al. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev (2011) 25(1):41-50. doi:10.1101/gad.1975111
70. Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, et al. Definition of pRB-and p53-dependent and-independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol (2007) 27(7):2452-65. doi:10.1128/MCB.01592-06
71. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell (2005) 8(1):19-30. doi:10.1016/j.devcel.2004.10.019
72. Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, Grossman T, et al. E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ (2009) 16(8):1156-66. doi:10.1038/cdd.2009.31
73. Wolyniec K, Shortt J, de Stanchina E, Levav-Cohen Y, Alsheich-Bartok O, Louria-Hayon I, et al. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood (2012) 120(4):822-32. doi:10.1182/blood-2011-10-387647
74. Liu M, Iavarone A, Freedman LP. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem (1996) 271(49):31723-8. doi:10.1074/jbc.271.49.31723
75. Cao L, Song Y, Tian B, Liu J, Liu B, Zhang J, et al. PML contributes to p53-independent p21 up-regulation in gamma-irradiation induced DNA damage responses. Chin Sci Bull (2011) 56(30):3148-54. doi:10.1007/s11434-011-4566-0
76. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science (2000) 287(5459):1804-8. doi:10.1126/science.287.5459.1804
77. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature (2009) 457(7225):51-6. doi:10.1038/nature07618
78. Insinga A, Cicalese A, Faretta M, Gallo B, Albano L, Ronzoni S, et al. DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions. Proc Natl Acad Sci U S A (2013) 110(10):3931-6. doi:10.1073/pnas.1213394110
79. Lee JY, Kim HS, Kim JY, Sohn J. Nuclear translocation of p21(WAF1/CIP1) protein prior to its cytosolic degradation by UV enhances DNA repair and survival. Biochem Biophys Res Commun (2009) 390(4):1361-6. doi:10.1016/j.bbrc.2009.10.160
80. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J (2001) 20(16):4547-59. doi:10.1093/emboj/20.16.4547
81. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KLB. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol (2006) 175(3):415-26. doi:10.1083/jcb.200607020
82. Lai HK, Borden KL. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA. Oncogene (2000) 19(13):1623-34. doi:10.1038/sj.onc.1203473
83. Zhong S, Hu P, Ye TZ, Stan R, Ellis NA, Pandolfi PP. A role for PML and the nuclear body in genomic stability. Oncogene (1999) 18(56):7941-7. doi:10.1038/sj.onc.1203367
84. McNally BA, Trgovcich J, Maul GG, Liu Y, Zheng P. A role for cytoplasmic PML in cellular resistance to viral infection. PLoS ONE (2008) 3(5):e2277. doi:10.1371/journal.pone.0002277
85. Geoffroy M-C, Chelbi-Alix MK. Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res (2011) 31(1):145-58. doi:10.1089/jir.2010.0111
86. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 442(7104):779-85. doi:10.1038/nature05029
87. Chen RH, Lee YR, Yuan WC. The role of PML ubiquitination in human malignancies. J Biomed Sci (2012) 19:81. doi:10.1186/1423-0127-19-81
88. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res (1999) 59(17):4175-9.
89. Grobelny JV, Godwin AK, Broccoli D. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci (2000) 113(Pt 24):4577-85.
90. Bøe SO, Simonsen A. Autophagic degradation of an oncoprotein. Autophagy (2010) 6(7):964-5. doi:10.4161/auto.6.7.13066
91. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell (2008) 132(1):27-42. doi:10.1016/j.cell.2007.12.018
92. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature (2008) 451(7182):1069-75. doi:10.1038/nature06639
93. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev (2010) 90(4):1383-435. doi:10.1152/physrev.00030.2009
94. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet (2009) 43:67-93. doi:10.1146/annurev-genet-102808-114910
95. Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol (2004) 36(12):2445-62. doi:10.1016/j.biocel.2004.02.002
96. Yecies JL, Manning BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (2011) 89(3):221-8. doi:10.1007/s00109-011-0726-6
97. Watson AS, Mortensen M, Simon AK. Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle (2011) 10(11):1719-25. doi:10.4161/cc.10.11.15673
98. Laane E, Pokrovskaja Tamm K, Buentke E, Ito K, Kharaziha P, Khahariza P, et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ (2009) 16(7):1018-29. doi:10.1038/cdd.2009.46
99. Isakson P, Bjørås M, Bøe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood (2010) 116(13):2324-31. doi:10.1182/blood-2010-01-261040
100. Wang Z, Cao L, Kang R, Yang M, Liu L, Zhao Y, et al. Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARa oncoprotein. Autophagy (2011) 7(4):401-11. doi:10.4161/auto.7.4.14397
101. Zhou W, Bao S. PML-mediated signaling and its role in cancer stem cells. Oncogene (2013). doi:10.1038/onc.2013.111. [Epub ahead of print].